Bristol-Myers Squibb vs Humana: why the prices moved differently

• ▲

  Reblozyl Sales Near $1.3 Billion, FDA Sets 2027 Decision Reblozyl sales hit nearly $1.3 billion in the first half of 2026, up 23%, as it helps replace older drugs losing patent protection. The FDA accepted a supplemental application for use in myelofibrosis-associated anemia, with a decision expected by March 2027. This supports future revenue growth and lifts BMY's outlook.

  Shows a key growth drug's strong sales and a regulatory step that could expand its use, directly supporting BMY's revenue replacement story.

• ▲

  Zenbexus Launch Advances with Onco360 Pharmacy Network Bristol selected Onco360 for the specialty pharmacy network of its newly approved myeloma drug Zenbexus, moving the launch forward. Getting the drug to patients is key to replacing revenue from older myeloma drugs facing generic competition. Successful rollout could add a new blockbuster stream over time.

  Highlights concrete progress in commercializing a new drug that is central to offsetting patent losses.

• ▲

  Bristol Raises Guidance and Builds $2.3 Billion Houston Campus Bristol raised its full-year revenue guidance to about $49–50 billion and announced a $2.3 billion manufacturing campus in Houston. The guidance raise signals confidence in the business, while the plant expands capacity for future drugs. Both support the stock by improving the profit outlook and long-term supply.

  Guidance raise and major investment show management's confidence and capacity for growth, key drivers for the stock.

• ▼

  Patent Cliff and Weak Financials Weigh on Sentiment Analysts warn that Bristol's low valuation reflects looming patent expirations on Revlimid, Pomalyst, and Eliquis, which will cause revenue declines. One report also flagged weak long-term financials: slow revenue growth, falling margins, and declining earnings per share. These concerns keep a lid on the stock despite new drug progress.

  Presents the main counterweight: patent losses and weak financial trends that could pressure the stock even as new drugs grow.

Based on 12 stories →

• ▲

  Growth Portfolio Now 56% of Revenue, EPS Estimates Raised Bristol's growth products (Opdivo, Camzyos, Sotyktu, etc.) now make up 56% of total revenue, up from 51.8% a year ago, with first-half sales up 13%. Analysts have raised 2026 EPS estimates to $6.91 from $6.34, reflecting confidence that new drugs are replacing older ones losing patent protection. This supports a higher stock price.

  Shows the core shift from legacy to growth products that is driving earnings upgrades and investor optimism.

• ▲

  Zenbexus (iberdomide) Wins FDA Approval and Shows Strong Phase 3 Data The FDA granted accelerated approval to Zenbexus for multiple myeloma, the first in a new drug class. In a Phase 3 trial, it doubled the rate of deep responses (MRD-negative complete responses) versus standard treatment. This adds a potential blockbuster revenue stream and validates Bristol's pipeline, lifting the stock.

  A new approved drug with superior efficacy data is a major growth catalyst that directly boosts future revenue expectations.

• ▲

  Sotyktu Shows Sustained Two-Year Efficacy in Psoriatic Arthritis Bristol's Sotyktu maintained strong efficacy and safety over two years in patients with psoriatic arthritis, with responses improving through week 104. This supports the drug's long-term use and potential to capture more market share in a large patient population, adding to revenue growth.

  Long-term data reinforces the commercial potential of a key growth product, supporting revenue forecasts.

• ▲

  Camzyos Approval Expanded to Pediatric Patients The FDA expanded Camzyos's label to include pediatric patients with obstructive hypertrophic cardiomyopathy, making it the only approved therapy for this age group. This broadens the patient pool and strengthens Camzyos's growth trajectory, a positive for Bristol's revenue outlook.

  Label expansion opens a new patient population, directly increasing the drug's market size and sales potential.

Based on 8 stories →

• ▲

  Zenbexus FDA Approval Adds New Myeloma Growth Driver The FDA approved Bristol's oral Zenbexus for relapsed multiple myeloma, a new revenue stream to help replace older drugs losing patent protection. It's an accelerated approval needing confirmatory trials and faces intense competition, so it builds gradually rather than instantly lifting the stock.

  This is a new drug approval that directly adds a future revenue driver for BMY.

• ▼

  J&J's Oral Psoriasis Pill Approved in China, Threatening Sotyktu Johnson & Johnson won Chinese approval for its once-daily oral psoriasis pill, which will compete with Bristol's Sotyktu in a market of over 8 million patients. This adds competitive pressure that could limit Sotyktu's growth in China, weighing on BMY's sentiment.

  New competitive threat in a key market that could slow BMY's psoriasis drug sales.

• ▲

  Five-Year Camzyos Data Reinforces Long-Term Heart Drug Profile Bristol presented five-year data showing its heart drug Camzyos keeps working safely, with most patients improving. This strengthens confidence in a key growth product and supports its use long-term, a positive for BMY's revenue outlook.

  New clinical data that supports the durability and safety of a key growth drug.

• ▼

  CAR-T Safety Concerns After Novartis Deaths; Bristol Pauses Similar Trials Novartis halted CAR-T trials after three patient deaths, and Bristol paused its own similar trials as a precaution. This raises regulatory and safety worries for Bristol's CAR-T programs, adding uncertainty that can pressure the stock until the reviews clear.

  New safety event that directly affects BMY's CAR-T development and investor risk perception.

• ▲

  Arlo-cel Meets Primary Endpoint in Phase 2 Myeloma Trial Bristol's experimental CAR-T therapy arlo-cel met its main goal in a mid-stage myeloma trial, showing strong response rates in hard-to-treat patients. This is a potential first-in-class treatment that could become a future growth driver, boosting optimism about the pipeline.

  New positive clinical trial result that advances a potential new therapy for BMY.

Based on 6 stories →

• ▲

  Bristol Raises 2026 Revenue Guidance on Eliquis Strength Bristol raised full-year 2026 revenue guidance to $49–$50 billion from $46–$47.5 billion, after Eliquis sales grew 19% to $8.6 billion in the first half. The company now expects Eliquis growth of 20–25% for the year, up from 10–15%, and a smaller decline in older drugs. This directly boosts earnings expectations and investor confidence, pushing BMY shares up.

  This is the most significant new positive catalyst, directly raising revenue and profit outlook.

• ▲

  Bristol Partners with Chai Discovery on AI Antibody Discovery Bristol announced a collaboration with Chai Discovery to use AI and machine learning for discovering new therapeutic antibodies. This aims to speed up drug discovery and strengthen the pipeline, supporting long-term growth. While the impact is not immediate, it reinforces Bristol's commitment to innovation and could lead to new revenue streams, positively influencing investor sentiment.

  This new partnership shows Bristol's ongoing investment in AI to enhance pipeline, a key long-term growth driver.

• ▲

  Bristol to Invest $2.3 Billion in Houston Manufacturing Plant Bristol announced a $2.3 billion investment in a new Houston manufacturing campus, part of a larger $40 billion U.S. investment pledge. The plant will produce small-molecule medicines, biologics, and antibody-drug conjugates, creating jobs and expanding capacity. This move supports long-term supply chain resilience and may ease tariff pressures, positively affecting BMY's outlook.

  This new capital investment demonstrates commitment to U.S. manufacturing and could mitigate tariff risks, a positive for the stock.

• ▼

  Revived $6.7 Billion Celgene Lawsuit Adds Legal Uncertainty A federal appeals court reinstated a $6.7 billion lawsuit alleging Bristol delayed FDA approval of certain drugs to avoid paying contingent value rights to former Celgene shareholders. This brings renewed legal and financial uncertainty, potentially leading to a large cash payout and weighing on investor sentiment. The risk premium on BMY may increase, pressuring the stock price.

  This new legal development introduces a significant potential liability, a negative factor for the stock.

Based on 9 stories →

• ▲

  Q2 earnings beat and raised guidance Bristol reported Q2 revenue of $12.97 billion, beating estimates, and raised full-year guidance. Strong sales of Eliquis and newer drugs like Camzyos and Reblozyl drove the beat. This shows the growth portfolio is replacing lost older-drug sales faster than feared, boosting investor confidence and supporting the stock price.

  This is a major positive event that directly impacts BMY's financial outlook and investor confidence.

• ▼

  AstraZeneca merger talks called off After reports of merger talks, AstraZeneca's board decided to call them off, and Reuters reported no discussions ever took place. The potential takeover premium evaporated, removing a catalyst that had briefly lifted BMY shares. This leaves BMY to face its patent cliff alone, weighing on sentiment.

  The merger speculation was a key driver of BMY's stock movement, and its termination is a significant negative development.

• ▲

  FDA approves ZENBEXUS for multiple myeloma The FDA granted accelerated approval to ZENBEXUS, a first-in-class CELMoD therapy, for relapsed multiple myeloma. This new treatment offers a potential revenue stream to help offset losses from older drugs facing patent expirations, strengthening BMY's oncology portfolio and long-term growth prospects.

  This is a new product approval that directly addresses BMY's need to replace lost revenue from expiring patents.

• ▲

  Expanded AI partnerships for drug discovery Bristol expanded its partnership with Nvidia to build a next-generation AI supercomputer and struck a deal with Schrödinger to deploy its AI co-scientist Bunsen. These investments aim to speed up drug discovery and reduce costs, supporting long-term pipeline efficiency and innovation.

  These partnerships highlight BMY's commitment to technological innovation, which could improve future drug development and cost efficiency.

Based on 11 stories →

• ▲

  Q2 beat and raised full-year guidance Bristol reported roughly $13.0 billion in quarterly revenue, beating expectations by $1.23 billion, with cancer drugs driving growth. Adjusted earnings per share jumped about 40% to $2.04. Management raised full-year revenue and profit guidance above consensus, signaling the growth portfolio is replacing lost older-drug sales faster than feared.

  This is the core fundamental news of the period and directly supports a higher valuation for BMY.

• ▲

  Reported AstraZeneca merger talks boost BMY shares The Financial Times and other outlets reported preliminary merger discussions between AstraZeneca and Bristol-Myers Squibb that could create a nearly $400 billion drugmaker. BMY shares rose about 8% in premarket trading before fading to near flat, as investors saw a possible takeover premium but also big antitrust hurdles and doubts a deal gets done.

  This is the single biggest new event moving BMY's stock this period and explains the sharp price reaction.

• ◆

  Deal skepticism and antitrust concerns cap the rally AstraZeneca shares fell about 9% while BMY's early 8% gain faded to near flat, showing the market doubts the deal's value and feasibility. Analysts flagged direct competition in lung cancer between Opdivo and Imfinzi, and estimated neither company has the standalone financial firepower to buy the other outright. A deal may never happen.

  It is the essential counterweight to the merger headline and explains why BMY's initial surge did not hold.

Based on 8 stories →

• ▼

  Cytokinetics launches Myqorzo, competing with Camzyos Cytokinetics launched Myqorzo in the U.S. and Germany for the same heart condition Camzyos treats. With over 275 prescribers already, this new rival could steal Camzyos sales, weighing on BMY's revenue growth.

  This is a new competitive threat that directly pressures a key BMY drug.

• ▼

  Trump administration drug-pricing deals include Bristol Myers Squibb Bristol agreed to voluntary most-favored-nation pricing, aligning some U.S. drug prices with lower prices abroad. With top sellers like Revlimid and Eliquis already facing patent expirations, this makes replacing lost revenue even harder.

  This is a new pricing agreement that directly affects BMY's revenue outlook.

• ▲

  FDA accepts mezigdomide application for multiple myeloma The FDA accepted Bristol's application for mezigdomide in relapsed multiple myeloma, with a decision expected by May 2027. The drug showed strong trial results, offering a potential new treatment to help offset lost sales from older drugs.

  This is a new regulatory milestone that advances a promising pipeline drug.

• ▲

  Bristol expands AI drug discovery with NVIDIA and new San Diego hub Bristol is building the most powerful AI supercomputer in life sciences with NVIDIA and opened a 427,000-square-foot San Diego research hub. These investments aim to speed up drug discovery and improve pipeline efficiency, supporting long-term growth.

  These new technology investments could enhance BMY's ability to develop new drugs faster.

Based on 9 stories →

• ▲

  Three pipeline wins in two weeks Bristol reported positive late-stage results for three experimental drugs: SUCCESSOR-2 in multiple myeloma, izalontamab brengitecan in breast and esophageal cancer, and a CAR-T therapy with a 96% response rate. New treatments help replace sales lost as older drugs face cheaper copies.

  This is the main new force lifting BMY: fresh pipeline data that can offset patent losses.

• ▼

  Congress probes China trials A House committee opened an investigation into Bristol over clinical trials at Chinese military hospitals and in Xinjiang. This adds legal and reputational risk, and could lead to restrictions or penalties, which weighs on the stock.

  It is a new regulatory threat that could hurt BMY's reputation and operations.

• ▼

  Medicare price negotiation risk Proposed changes would make Medicare drug price negotiation permanent from 2029 and tighten rules on fixed-combination drugs. This could pressure future U.S. prices for some Bristol medicines, though legal challenges and a broad product mix may soften the blow.

  It flags a new pricing risk that could lower BMY's future revenue.

• ▼

  Roche rival beats Krazati Roche's divarasib outperformed Bristol's Krazati in a Phase III lung cancer trial, meeting survival goals. This competitive threat could erode Krazati's market share and future sales, a negative for BMY.

  It shows a new competitive loss that could reduce BMY's oncology revenue.

Based on 7 stories →

• ▲

  Star Ratings Recovery Restores Bonus Payments CMS upgraded Humana's largest Medicare Advantage contract to 4 stars for 2027, and 95% of members will be in 4-star-plus plans, up from 20%. This restores federal quality bonus payments, boosting future earnings and lifting the stock 15%.

  This is the main new event that directly answers why HUM is moving, with a clear positive impact.

• ▲

  Analyst Upgrade on Improved Earnings Outlook Baird upgraded Humana to Outperform with a $596 price target, up from $390, citing confidence in $35-plus of 2028 adjusted EPS. This analyst endorsement reinforces the positive sentiment from the Star Ratings news.

  It shows a direct analyst reaction to the improved fundamentals, supporting the stock's move.

• ▲

  Expanded Coverage for Incontinence Device Humana will cover BlueWind Medical's Revi System for urgency urinary incontinence, expanding treatment access for its 11 million Medicare Advantage enrollees. This is a minor positive but shows Humana's role in adopting new technologies.

  It is a new coverage decision that could marginally improve Humana's reputation and member satisfaction.

• ▼

  Medicare Advantage Industry Retrenchment Centene is exiting 344 counties and three states for 2027, and Humana plans to exit 57 counties and Minnesota, as premiums are expected to decline 16.5%. This industry-wide pullback reflects ongoing pressure on Medicare Advantage profitability.

  It provides context on the challenging Medicare Advantage environment, a counterweight to the positive Star Ratings news.

Based on 8 stories →

• ▼

  Humana drops 600,000 Medicare Advantage members for 2027 Humana is cutting about 600,000 members from its Medicare Advantage plans next year, its second straight year of big cuts, to protect profit margins as medical costs rise. Fewer members means less premium revenue, which pressures the stock, though it may help margins.

  This is the core new event driving Humana's outlook and was confirmed in this period.

• ▲

  Star Ratings recovery targeted as key catalyst Humana aims to return to top-quartile Star Ratings by 2028, which would boost bonus payments and plan economics. Early progress is encouraging, and the October CMS ratings release is the next test. A rebound could support the stock, though shares already trade at a high valuation.

  Star Ratings recovery is a major potential upside driver for Humana's turnaround and margins.

• ▼

  Medicare fraud settlement and upcoding scrutiny The Villages Health settled a $541.5 million Medicare fraud case over inflated diagnosis codes. Humana's CenterWell unit is shielded from direct payment, but Humana received inflated payments and is returning overpayments. The case signals heightened government scrutiny on risk-adjustment practices, a regulatory risk for Humana.

  This highlights a regulatory overhang that could affect Humana's payments and reputation.

• ▼

  Sector-wide cost pressures and macro headwinds Managed care stocks, including Humana, fell after CVS Health warned of elevated medical costs. Rising oil prices and Treasury yields added to market pressure. These sector-wide concerns weigh on Humana's stock, though they are not specific to the company.

  This explains a broad negative sentiment affecting Humana's price during the period.

Based on 6 stories →

• ▼

  Medicare star rating drop cuts 2026 profit outlook Humana lowered its full-year GAAP earnings target to at least $6.52 per share from $8.36 because fewer plans earned four stars or more, reducing federal quality bonuses. This directly cuts expected profit and is the main reason the stock fell about 9% premarket.

  This is the biggest new negative event and explains the profit outlook cut.

• ▲

  Q2 earnings beat on membership and revenue growth Humana reported adjusted earnings of $7.61 per share, beating estimates by over 20%, with revenue up 26% to $40.9 billion and medical membership up 20.7% to 17.9 million. Strong results show the core business is growing, which supports the stock.

  This is a new positive counterweight to the profit outlook cut.

• ▼

  End of Medicare Part D subsidy raises 2027 premiums The Trump administration ended a subsidy that gave insurers about $3.6 billion in 2026. Without it, most enrollees will pay more in 2027, and insurers like Humana may see lower government payments and pressure on Part D margins, which is a negative for future profits.

  This is a new regulatory change that affects Humana's future Medicare Part D business.

• ▲

  Operational streamlining and growth initiatives Humana is targeting a 3% margin by 2028, exiting weaker Medicare Advantage plans, and expanding Medicaid and home health through a $900 million divestiture and the MaxHealth acquisition. These moves aim to improve long-term profitability and offset star rating issues.

  This shows management's plan to fix margins and grow, which is new and relevant to the big picture.

Based on 7 stories →

• ▲

  Illinois Medicaid win expands members Humana won a statewide Illinois Medicaid contract, adding members across all 102 counties starting January 2027. More members mean more premium revenue, which supports future earnings and makes the stock more attractive.

  New contract directly expands Humana's revenue base.

• ▼

  AI gains may be competed away UBS says hospitals may benefit more from AI than insurers because insurers' efficiency gains are easily copied and competed away through pricing. This limits how much Humana can improve margins from AI, a headwind for profit growth.

  Analyst view questions durability of insurer AI margin gains.

• ▼

  Medicare Advantage denial scrutiny A New York Times report highlighted high denial rates for rehab care among major Medicare Advantage insurers, including Humana. This raises regulatory and reputational risk, which could lead to stricter rules or fines, pressuring the stock.

  Regulatory scrutiny can hurt Humana's Medicare Advantage business.

• ▲

  Margin recovery plan and strong Q1 Humana beat Q1 earnings estimates and targets insurance margins above 3% by 2028, with disciplined pricing and cost cuts. Strong results and a clear profit plan boost investor confidence, pushing the stock up.

  New earnings and margin targets show improving profitability.

• ▲

  CenterWell drives growth beyond insurance CenterWell revenue jumped 19.7% to $6.1 billion, with growth in primary care, home health, and pharmacy. This diversification reduces reliance on insurance and adds a steady profit stream, supporting the stock.

  CenterWell's strong growth is a key new driver of Humana's value.

Based on 6 stories →